The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Ultragenyx Pharmaceutical Inc shares valued at $89,923 were sold by Sanders Corazon (Corsee) D. on Jun 20 ’25. At $37.39 per share, Sanders Corazon (Corsee) D. sold 2,405 shares. The insider’s holdings dropped to 15,344 shares worth approximately $0.42 million following the completion of this transaction.
Before that, Crombez Eric had sold 520 shares from its account. In a trade valued at $20,405, the EVP and Chief Medical Officer traded Ultragenyx Pharmaceutical Inc shares for $39.24 each. Upon closing the transaction, the insider’s holdings decreased to 520 shares, worth approximately $1.95 million.
Analysts at William Blair started covering the stock with ‘”an Outperform”‘ outlook in a report released in late May. As of June 06, 2024, Goldman has increased its “Neutral” rating to a “Buy” for RARE. Earlier on April 22, 2024, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for RARE stock.
Analyzing RARE Stock Performance
On last trading session, Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] rose 0.66% to $27.32. The stock’s lowest price that day was $26.85, but it reached a high of $27.53 in the same session. During the last five days, there has been a surge of approximately 0.07%. Over the course of the year, Ultragenyx Pharmaceutical Inc shares have dropped approximately -39.61%.
Support And Resistance Levels for Ultragenyx Pharmaceutical Inc (RARE)
RSI (Relative Strength Index) is 34.09 on the 14-day chart, showing neutral technical sentiment.
Is Ultragenyx Pharmaceutical Inc subject to short interest?
Stocks of Ultragenyx Pharmaceutical Inc saw a sharp rise in short interest on 2025-07-15 jumping by 2.72 million shares to 8.8 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 6.08 million shares. A jump of 30.91% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.81 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.81.
Which companies own the most shares of Ultragenyx Pharmaceutical Inc (RARE)?
In terms of Ultragenyx Pharmaceutical Inc share price expectations, FactSet research, analysts set an average price target of 89.5 in the next 12 months, up nearly 229.77% from the previous closing price of $27.14. Analysts anticipate Ultragenyx Pharmaceutical Inc stock to reach 115 by 2025, with the lowest price target being 64. In spite of this, 16 analysts ranked Ultragenyx Pharmaceutical Inc stock as Buy at the end of 2025. On December 08, 2023, Wells Fargo assigned a price target of “an Overweight” to the stock and initiated coverage with a $72.
